signal/raiseTrack rounds
Series D+Healthtech & bio · Beijing

MegaRobo raises nearly $200m in new round joined by Oman's sovereign wealth fund

The Chinese lab-automation company did not name the round, which follows a Series C of nearly $300m and brings its total funding to about $600m. CMB International invested for the first time.

s/rFunding deskEast Asia · 3 min read

MegaRobo Technologies, a Chinese company that builds automated laboratories and software for AI-driven science, said on 18 November 2026 that it had raised nearly $200m in a new financing round. Oman Investment Authority, the sovereign wealth fund of Oman, joined the round.

Existing investors Asia Investment Capital, Granite Asia and Sinovation Ventures put in more money, and CMB International took part for the first time. The company did not give the round a series name, identify a lead investor or disclose a valuation. Chinese venture news site PEdaily listed two further participants, 苏创投 and 三江招商集团.

The announcement was issued from Suzhou, and PEdaily referred to the company by the name of its Suzhou entity, 苏州镁伽科技有限公司. DealStreetAsia described MegaRobo as headquartered in Beijing and reported that it was founded in 2016.

“The first generation of AI learned from humanity's accumulated knowledge. The next generation will increasingly learn by acting in the physical world - through experiments, production and continuous feedback. That shift changes AI from a system that interprets the world into one that can help create new knowledge, materials, processes and products. MegaRobo is building the infrastructure for that transition.”Daniel Huang, Founder and CEO, MegaRobo

What MegaRobo does

MegaRobo describes its business as infrastructure that lets AI act in the physical world. Its core platform, which it calls the One Intelligence Stack, combines models and agents, data, workflows, software, scientific instruments, robotics and automation, so that a system can plan an experiment, carry it out, observe the result and use what it learned in the next step.

Science, and drug research in particular, is the first market. The company said it has supplied products and technology to more than 500 customers, including global drugmakers, drug discovery firms, biotech companies and research institutes, for work ranging from early research and target discovery to drug screening and candidate optimisation. DealStreetAsia gave a larger client count of more than 1,200 and reported that about 80% of revenue is earned in China.

Through a service called Megalaxy Lab, researchers and AI agents can set up experiments, send them to automated lab systems and receive results in a machine-readable form. MegaRobo said the service has been used by more than 200 customers. With Tencent Cloud and Twist Bioscience it has launched Poreva Open, an AI protein design competition in which Megalaxy Lab will test more than 10,000 designed sequences in its wet labs.

Who invested

Liu Erh Fei, founding partner and chief executive of Asia Investment Capital, said the firm was adding to its holding because MegaRobo had won customers' trust, turned its technology into commercial products and shown it can combine AI, software and hardware.

MegaRobo said it has raised about $600m to date. That includes a Series C of nearly $300m co-led by Goldman Sachs Alternatives, Asia Investment Capital and Granite Asia, with Pavilion Capital, part of Temasek's Seviora Group, also investing. DealStreetAsia dated that round to June 2022 and said it took the company's valuation above $1bn.

Other long-term backers named by the company are Sinovation Ventures, Joy Capital and MPCi. WuXi AppTec and Bosch Ventures invested at an earlier stage as industry investors.

What the money is for

MegaRobo said the new funds will go into core technology, the international growth of its AI for Science business and infrastructure that lets AI work in more complex physical settings. It said it is expanding across North America, Europe, the Middle East and Asia, and that it intends to apply the same architecture beyond science to other systems involving instruments, machines, materials and production processes.

Founder and chief executive Daniel Huang (黄瑜清) described the shift as AI moving from learning out of accumulated human knowledge to learning by acting in the real world through experiments and production. According to DealStreetAsia, Huang said the company remains in the queue for a Hong Kong initial public offering after filing in mid-2025.

Company website: megarobo.com